MX2021008974A - Tratamiento para los trastornos de la piel con composiciones combinadas tópicas de tapinarof. - Google Patents

Tratamiento para los trastornos de la piel con composiciones combinadas tópicas de tapinarof.

Info

Publication number
MX2021008974A
MX2021008974A MX2021008974A MX2021008974A MX2021008974A MX 2021008974 A MX2021008974 A MX 2021008974A MX 2021008974 A MX2021008974 A MX 2021008974A MX 2021008974 A MX2021008974 A MX 2021008974A MX 2021008974 A MX2021008974 A MX 2021008974A
Authority
MX
Mexico
Prior art keywords
treatment
skin disorders
compositions
combination compositions
topical
Prior art date
Application number
MX2021008974A
Other languages
English (en)
Inventor
Moshe Arkin
Original Assignee
Sol Gel Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sol Gel Tech Ltd filed Critical Sol Gel Tech Ltd
Publication of MX2021008974A publication Critical patent/MX2021008974A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan composiciones combinadas tópicas que comprenden una dosis terapéuticamente eficaz de tapinarof y una dosis terapéuticamente eficaz de al menos un agente activo adicional, seleccionado de al menos un corticosteroide, calcipotrieno, al menos un inhibidor de JAK y combinaciones de los mismos y un vehículo adecuado para la administración tópica. Las composiciones anteriores son útiles para el tratamiento, prevención o mejora de los trastornos de la piel seleccionados de la psoriasis y la dermatitis atópica y presentan efectos sinérgicos o aditivos que permiten reducir las dosis de los agentes activos en las composiciones.
MX2021008974A 2019-01-27 2020-01-27 Tratamiento para los trastornos de la piel con composiciones combinadas tópicas de tapinarof. MX2021008974A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962797298P 2019-01-27 2019-01-27
PCT/IL2020/050103 WO2020152690A1 (en) 2019-01-27 2020-01-27 Treatment of skin disorders with topical tapinarof combination compositions

Publications (1)

Publication Number Publication Date
MX2021008974A true MX2021008974A (es) 2021-10-26

Family

ID=71736580

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008974A MX2021008974A (es) 2019-01-27 2020-01-27 Tratamiento para los trastornos de la piel con composiciones combinadas tópicas de tapinarof.

Country Status (8)

Country Link
US (1) US20220008356A1 (es)
EP (1) EP3914231A4 (es)
JP (1) JP2022518912A (es)
KR (1) KR20210121179A (es)
CN (1) CN113473969A (es)
CA (1) CA3127856A1 (es)
MX (1) MX2021008974A (es)
WO (1) WO2020152690A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220287990A1 (en) * 2019-07-24 2022-09-15 Sol-Gel Technologies Ltd. Topical jak inhibitor combination compositions for treatment of inflammatory skin conditions
CN116265421B (zh) * 2021-12-17 2024-01-02 上海泽德曼医药科技有限公司 用于预防或治疗中枢神经***相关疾病的化合物
WO2023109859A1 (zh) * 2021-12-15 2023-06-22 上海泽德曼医药科技有限公司 二苯乙烯类化合物及其在用于预防和/或治疗中枢神经***相关疾病中的应用
CN116265017A (zh) * 2021-12-16 2023-06-20 上海泽德曼医药科技有限公司 一种包含本维莫德和皮质类固醇的药物组合物
WO2024013741A1 (en) * 2022-07-11 2024-01-18 Sol-Gel Technologies Ltd. Topical tapinarof composition for treating skin disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015086693A1 (en) * 2013-12-11 2015-06-18 Almirall, S.A. Pyrazolopyrimidin-2-yl derivatives as jak inhibitors

Also Published As

Publication number Publication date
US20220008356A1 (en) 2022-01-13
JP2022518912A (ja) 2022-03-17
CA3127856A1 (en) 2020-07-30
KR20210121179A (ko) 2021-10-07
EP3914231A4 (en) 2022-10-19
EP3914231A1 (en) 2021-12-01
WO2020152690A1 (en) 2020-07-30
CN113473969A (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
MX2021008974A (es) Tratamiento para los trastornos de la piel con composiciones combinadas tópicas de tapinarof.
CL2023000847A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
ZA202102628B (en) 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
MX2019003397A (es) Metodos para tratar trastornos mitocondriales y metabolicos.
MX2018003028A (es) Reduccion de los niveles o de la actividad de los linfocitos t reguladores sistemicos para el tratamiento de enfermedades y lesiones del sistema nervioso central (snc).
MX2019003981A (es) Formulaciones para la administracion de eflornitina.
MX2018012719A (es) Ram negativas para tratar la dermatitis atopica.
WO2017042633A3 (en) Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
WO2018102687A3 (en) Combination therapy for treating cancer
MX365366B (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
ZA202109179B (en) Compounds comprising n-methyl-2-pyridone, and pharmaceutically acceptable salts
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
SG11201908234WA (en) Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer
MX2021011488A (es) Compuestos y usos de estos.
PH12021550965A1 (en) Combination therapy for treatment of hematological diseases
MX2021009535A (es) Uso de composiciones tópicas de inhibidores de braf para el tratamiento de la dermatitis por radiación.
MX2020011295A (es) Tratamiento de dermatitis atopica.
MX2020009942A (es) Compuestos y usos de los mismos.
MX2021000868A (es) Uso de especies gram negativas para tratar la dermatitis atopica.
CR20220280A (es) Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2
MX2020006309A (es) Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis.
PH12020551179A1 (en) Methods for treating mitochondrial disorder
WO2020141828A3 (en) Anticancer compositions comprising immune checkpoint inhibitors
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.